"Researchers are making progress toward understanding how some cases of glaucoma begin. A new study from the National Eye Institute reveals that myocilin—a protein linked to a significant fraction of glaucoma—is needed to insulate peri"...
- Patient Information:
Details with Side Effects
XIBROM (bromfenac ophthalmic solution ) ophthalmic solution is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.
DOSAGE AND ADMINISTRATION
For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of XIBROM (bromfenac ophthalmic solution ) ophthalmic solution should be applied to the affected eye(s) two times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.
XIBROM™ (bromfenac ophthalmic solution) 0.09% is supplied in a white LDPE plastic squeeze bottle with a 15 mm LDPE white dropper-tip and 15 mm polypropylene gray cap as follows:
NDC 67425-004-50 5 mL in 10 mL container
NDC 67425-004-12 2.5 mL in 7.5 mL container
Store at 15-25 °C (59-77 °F)
Manufactured for : ISTA Pharmaceuticals, Inc. Irvine, CA 92618. By: Bausch & Lomb Incorporated Tampa, FL 33637, Under license from: Senju Pharmaceutical Co., Ltd. Osaka, Japan 541-0046, Revised December 2008.
Last reviewed on RxList: 6/23/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Xibrom Information
Xibrom - User Reviews
Xibrom User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.